¿Cuál es el fundamento de las terapias basadas en la utilización de células t modificadas (car- t-cells)?
DOI:
https://doi.org/10.51987/Rev.Hosp.Ital.B.Aires.v38i3.569Downloads
References
Billingham RE, Brent L, Medawar PB. Quantitative Studies on Tissue Transplantation Immunity. II. The Origin, Strength and Duration of Actively and Adoptively Acquired Immunity. Proc R Soc London. 1954; 143(910):58-80. DOI: https://doi.org/10.1098/rspb.1954.0054
Smyth MJ. Multiple approaches to immunotherapy - the new pillar of cancer treatment. Immunol Cell Biol. 2017; 95(4):323-324. DOI: https://doi.org/10.1038/icb.2017.9
Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014; 371(16):1507–17. DOI: https://doi.org/10.1056/NEJMoa1407222
Brentjens RJ, Davila ML, Riviere I, et al. D19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013; 5(177):177ra38. DOI: https://doi.org/10.1126/scitranslmed.3005930
Tran E, Longo DL, Urba WJ, et al. A Milestone for CAR T Cells. N Engl J Med 2017; 377:2593-2596 DOI: https://doi.org/10.1056/NEJMe1714680
Downloads
Published
Issue
Section
License
Copyright (c) 2018 Revista del Hospital Italiano de Buenos Aires
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
